Question

as-120 overcomes resistance to atp-competitive fgfr inhibitors in patients with fgfr2 fusion–positive intrahepatic cholangiocarcinom

Answer 1

TAS-120 helps the patients in becoming resistant to BGJ398 and FGFR2 mutations.

Anti-tumor activity has been observed in the patient with intrahepatic cholangiocarcinoma (ICC) that activates ATP-competitive fibroblast growth factor receptor gene fusions. This results in resistance and results in the development of mutation of FGFR2 kinase.

It was further reported in 4 patients with FGFR2 that they developed Debio 1347. It was due to the activation of TAS-120 that fight the FGFR2.TAS-120 is the inhibitor of FGFR and it is irreversible. In patients with FGFR2, an increase in the duration of FGFR inhibition, FGFR inhibitors can be sequenced in a planned manner along with the biopsy.

TAS-120 helps the patients in becoming resistant to BGJ398 and FGFR2 mutations.

To know more about mutation, refer to the below link:

brainly.com/question/9598940

#SPJ4